The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
Human ARPP19 encodes cAMP-regulated phosphoprotein 19, a small, intrinsically disordered member of the endosulfine family. It is not an enzyme, transporter, or structural scaffold in the conventional sense. Its best-supported primary function is as a phosphorylation-controlled inhibitor and slowly dephosphorylated substrate of PP2A-B55, the phosphatase that removes many cyclin-dependent-kinase phosphates. Phosphorylation of human ARPP19 at Ser62 by MASTL/Greatwall converts it into the functionally active PP2A-B55 inhibitor, thereby maintaining phosphorylation of mitotic substrates and promoting orderly mitotic progression. A second site, Ser104, is targeted by PKA and, in human platelets, by cAMP/cGMP-dependent signaling; it does not itself confer PP2A inhibition and its physiological role in human dividing cells remains less firmly established. (labbe2021thestudyof pages 1-2, kumm2020thecellcycle pages 1-3)
The strongest direct mammalian evidence indicates that ARPP19 is the principal MASTL effector for mitosis, whereas its paralog ENSA has a more prominent role in S phase. Mouse Arpp19 deletion causes severe early embryonic defects and premature dephosphorylation of mitotic substrates. Human evidence includes phosphorylation-dependent PP2A regulation in platelets and elevated expression in some cancers, but ARPP19 is not currently a validated clinical drug target or diagnostic biomarker. (hached2019ensaandarpp19 pages 1-2, kumm2020thecellcycle pages 1-3, song2014increasedarpp19expression pages 4-8)
The requested target is internally consistent:
Literature explicitly identifies ARPP19 as a cAMP-regulated, endosulfine-family PP2A regulator. The protein is ubiquitously expressed and intrinsically disordered rather than a compact enzyme. Human biophysical work estimates a molecular mass of approximately 12.6 kDa, despite anomalous behavior resembling an approximately 20-kDa globular protein during size-exclusion chromatography—consistent with an extended disordered conformation. NMR/SAXS analyses identify transiently structured regions rather than a stable catalytic fold. (thapa2021structuralinsightofa pages 53-56, thapa2021structuralinsightof pages 27-31)
Two closely related proteins must not be conflated with the target:
No evidence of a different human gene using the same ARPP19 symbol was found. The research below therefore concerns the correct protein, while explicitly separating ARPP16-, ENSA-, and nonhuman findings.
ARPP19 is a nonenzymatic phosphatase regulator. It neither catalyzes a chemical reaction nor transports a substrate. Its functional “substrate specificity” is therefore best expressed as target-complex specificity: activated ARPP19 primarily inhibits PP2A holoenzymes containing a B55 regulatory subunit, thereby indirectly preserving phosphorylation on the broad class of mitotic proteins normally dephosphorylated by PP2A-B55.
The central reaction can be summarized as:
MASTL/Greatwall + ARPP19 → ARPP19-pSer62 → inhibition of PP2A-B55 → persistence of CDK-dependent mitotic phosphorylation.
Mechanistically, phospho-ARPP19 is not merely a steric inhibitor. It behaves as a high-affinity, slowly dephosphorylated competitive substrate of PP2A-B55. By occupying the phosphatase for an extended interval, it limits access of ordinary mitotic substrates. Xenopus depletion experiments showed that B55 removal completely blocked ARPP19-pS67 dephosphorylation, supporting PP2A-B55 as both the inhibited enzyme and the phosphatase that ultimately processes ARPP19. (labbe2021thestudyof pages 1-2)
Species-specific numbering is a major source of confusion:
| ARPP19 state/site | Modifying enzyme or signal | Direct molecular consequence | Biological context or outcome | Evidence system and caveat |
|---|---|---|---|---|
| Unphosphorylated ARPP19 | Basal state; absence of activating phosphorylation | Small, intrinsically disordered endosulfine-family protein. Binding to the PP2A scaffold A subunit may be phosphorylation-independent, but potent PP2A-B55 inhibition requires activating phosphorylation. | Functions as a phosphorylation-responsive regulator rather than an enzyme; mammalian ARPP19 is predominantly associated with mitotic control. | Human ARPP19 structural and biophysical work supports intrinsic disorder and micromolar PP2A-A binding; this interaction alone does not establish PP2A-B55 inhibition (thapa2021structuralinsightofa pages 53-56, thapa2021structuralinsightof pages 27-31) |
| pS62 in human; pS67 in canonical Xenopus ARPP19 | MASTL/Greatwall, activated within the cyclin–CDK mitotic network | Converts ARPP19 into a high-affinity PP2A-B55 inhibitor and slowly dephosphorylated competitive substrate, protecting CDK-phosphorylated proteins from premature dephosphorylation. | Supports mitotic entry and progression and stable mitotic-substrate phosphorylation; only pS62, not pS104, inhibited PP2A in human platelets. | Direct human-platelet biochemical evidence supports S62-dependent inhibition; detailed affinity, kinetics, and feedback mechanisms derive mainly from Xenopus oocytes or egg extracts. Mouse genetics supports a nonredundant mitotic role (labbe2021thestudyof pages 1-2, hached2019ensaandarpp19 pages 1-2, kumm2020thecellcycle pages 1-3) |
| pS104 in human; pS109 in Xenopus | PKA downstream of cAMP; PKG-associated phosphorylation after cGMP elevation in human platelets | Human platelet pS104 is dephosphorylated by PP2A but does not itself inhibit PP2A. In Xenopus, pS109 antagonizes acquisition or persistence of the Greatwall-site phosphorylation state. | In Xenopus oocytes, pS109 maintains prophase-I arrest, while its dephosphorylation permits meiotic resumption. In human platelets, cAMP- or cGMP-elevating agents increase pS104, but its physiological output remains less defined. | The meiotic-arrest function is model-organism evidence and should not be assigned directly to human somatic cells. Human evidence is strongest in anucleate platelets, where PKA and PKG pathways target this site (labbe2021thestudyof pages 1-2, lemonnier2021themphaseregulatory pages 14-14, kumm2020thecellcycle pages 1-3) |
| PP2A-B55-bound phospho-ARPP19 | Recognition of MASTL/Greatwall-phosphorylated ARPP19 by PP2A-B55 | ARPP19 behaves as a slowly processed competitive substrate: tight engagement and slow dephosphorylation suppress access of ordinary PP2A-B55 substrates. | Delays dephosphorylation of mitotic proteins, reinforcing the high-phosphorylation state required during M phase. | Mechanistic kinetics and B55-depletion evidence are principally from Xenopus extracts; mammalian MEF loss-of-function produces premature mitotic-substrate dephosphorylation consistent with the same mechanism (labbe2021thestudyof pages 1-2, hached2019ensaandarpp19 pages 10-13) |
| PP2A-B55-mediated ARPP19 dephosphorylation | Reactivated PP2A-B55; reduced PKA or Greatwall signaling | Removes pS104/pS109 and eventually pS62/pS67; dephosphorylation relieves phosphatase inhibition and creates feedback between the two ARPP19 sites. | Enables meiotic resumption through pS109 removal and contributes to ordered mitotic exit through loss of pS67-dependent PP2A-B55 inhibition. | Direct dual-site feedback was defined in Xenopus. Human platelets show PP2A-dependent dephosphorylation of both S62 and S104 but do not model nuclear mitosis (labbe2021thestudyof pages 1-2, lemonnier2021themphaseregulatory pages 14-14, kumm2020thecellcycle pages 1-3) |
| PP2A-B55–ARPP19 structural complex and FAM122A transition | Sequential control involving FAM122A displacement and phosphorylated ARPP19 engagement | 2024 cryo-EM, NMR, and pull-down work showed that ARPP19 contacts multiple B55 surfaces, predominantly B55 helix α2. ARPP19 and FAM122A can bind simultaneously in an intermediate state, contrary to a strictly mutually exclusive model. | Refines mitotic-entry models: FAM122A may initiate PP2A-B55 inhibition, followed by stable phosphorylated-ARPP19 inhibition after FAM122A dissociation. | Structural evidence defines the interaction architecture, but the retrieved excerpt does not specify the ARPP19 species or fully establish the proposed handoff kinetics in intact human cells (padi2024cryoemstructuresof pages 8-9) |
Table: Evidence map of ARPP19 phosphorylation states, upstream signals, PP2A-B55 regulation, and biological outcomes. It distinguishes direct human evidence from mechanistic findings in mouse and Xenopus systems.
A major 2024 development was the cryo-EM analysis of PP2A-B55 complexes with ARPP19 and FAM122A. ARPP19 was found to engage multiple surfaces on B55, with a predominant contact involving B55 helix α2. Contrary to a simple mutually exclusive model, NMR and pull-down experiments indicated that ARPP19 and FAM122A can occupy PP2A-B55 simultaneously in an intermediate complex. The proposed model is that FAM122A contributes to initial PP2A-B55 inhibition at mitotic entry, then dissociates so phospho-ARPP19 can establish the fully inhibitory state. The work was published in Nature, volume 625, on 4 January 2024; the retrieved record did not expose a DOI. (padi2024cryoemstructuresof pages 8-9)
This structural result complements a 2024 EMBO Journal study proposing that FAM122A-mediated inhibition and rising cyclin-A/CDK activity initiate mitosis before full MASTL activation; MASTL-phosphorylated ARPP19/ENSA then takes over PP2A-B55 inhibition through mitosis. DOI: https://doi.org/10.1038/s44318-024-00054-z, published February 2024.
ARPP19 operates in the cyclin–CDK–MASTL–ARPP19–PP2A-B55 switch:
The mechanism is a bistable regulatory switch rather than a linear pathway: CDK activity promotes MASTL and ARPP19 activation, while PP2A-B55 opposes the same mitotic phosphorylation program. Detailed kinetic evidence from Xenopus shows that phospho-S67 ARPP19 binds PP2A-B55 with high affinity and is processed slowly. Wild-type dephosphorylation began at about 8 minutes and was complete at approximately 30 minutes in kinase-inactivated extracts; mutation of a nearby KKR motif modestly delayed completion to approximately 40 minutes without preventing PP2A-B55 association. (labbe2021thestudyof pages 1-2)
The second phosphorylation site creates additional feedback. In Xenopus oocytes, PKA-dependent S109 phosphorylation maintains prophase-I arrest; reduction of PKA activity permits PP2A-B55δ to remove this phosphate, enabling meiotic resumption. Later, Greatwall-dependent S67 phosphorylation inhibits PP2A-B55δ and stabilizes M-phase. This establishes ARPP19 as a signal integrator between cAMP/PKA and the core cell-cycle machinery. However, this meiotic-arrest mechanism is directly demonstrated in amphibian oocytes and should not automatically be assigned to human somatic cells. DOI: https://doi.org/10.1038/s41467-021-22124-0, published October 2021. (lemonnier2021themphaseregulatory pages 14-14)
ARPP19 is a soluble intracellular protein without a transmembrane segment, signal peptide, or extracellular catalytic role. Available mammalian evidence places ARPP16/ARPP19 in the cytosol of striatal neurons and tissue, while ectopically expressed Arpp19 in mouse embryonic fibroblasts has been reported in both cytoplasm and nucleus. The latter distribution is compatible with access to PP2A-B55 and mitotic substrates on both sides of the interphase nuclear envelope and throughout the cell after nuclear-envelope breakdown. (andrade2017arpp16isa pages 4-4)
The safest functional annotation is therefore intracellular, predominantly nucleocytoplasmic/cytosolic, with no evidence that ARPP19 is secreted or membrane embedded. Its precise endogenous localization through each phase of the human cell cycle remains less completely mapped than its biochemical function.
Human platelets provide unusually clean evidence because they contain the pathway despite being anucleate. Proteomics detected ARPP19, ENSA, and multiple PP2A subunits, including seven B-subunits. Agents elevating cAMP or cGMP increased ARPP19-S104 phosphorylation, whereas PP2A inhibition with okadaic acid increased S62 phosphorylation. Platelet PP2A dephosphorylated both sites, but only S62-phosphorylated ARPP19 inhibited PP2A. Low-dose okadaic acid reduced thrombin-induced aggregation and increased phosphorylation of VASP, Akt, p38, and ERK1/2, connecting the pathway to platelet signaling beyond nuclear cell division. DOI: https://doi.org/10.3390/cells9020472, published February 2020. (kumm2020thecellcycle pages 1-3)
This is strong direct human evidence for the biochemical distinction between the two sites. It does not, however, demonstrate ARPP19’s mitotic function because platelets do not divide.
Conditional mouse genetics provides the clearest organism-level evidence that ARPP19 and ENSA are not interchangeable. Homozygous Arpp19 deletion was embryonically lethal; no homozygous-null animals were born, and 100% of 39 Arpp19-null embryos examined at E8.5 displayed severe abnormalities. Arpp19-null mouse embryonic fibroblasts had greatly reduced viability and premature dephosphorylation of key cyclin-B/CDK1 substrates during mitotic progression, consistent with insufficient PP2A-B55 inhibition. Mitotic entry itself was relatively preserved, and S phase was not detectably perturbed. ENSA expression did not compensate for ARPP19 loss. By contrast, Ensa loss principally disrupted S phase and was not required for normal early development at E8.5. DOI: https://doi.org/10.1083/jcb.201708105, published January 2019. (hached2019ensaandarpp19 pages 1-2, hached2019ensaandarpp19 pages 10-13)
A 2023 follow-up in Mastl conditional-knockout MEFs found Arpp19 expression significantly higher than Ensa expression. Arpp19 silencing reduced proliferation, whereas Ensa silencing did not. Wild-type Arpp19 or phosphomimetic S67D partially restored the duration of mitotic arrest and CDK1-substrate phosphorylation after Mastl loss, as did B55δ silencing, but neither rescued the proliferation block. The authors concluded that ARPP19 is the major MASTL substrate during MEF mitosis, while also showing that MASTL has essential functions not fully replaced by manipulating this single effector. DOI: https://doi.org/10.1515/tjb-2022-0191, published March 2023. (diril2023geneticdissectionof pages 2-3, diril2023geneticdissectionof pages 9-12, diril2023geneticdissectionof pages 1-2)
Most residue-level kinetic and meiotic evidence derives from Xenopus oocytes and egg extracts. These studies established high-affinity, slow-substrate inhibition of PP2A-B55 by pS67-ARPP19, PKA control through S109, and feedback between the two sites. These are highly informative because the pathway is conserved, but the exact meiotic phenotypes and residue numbers must be labeled as Xenopus rather than human. DOI: https://doi.org/10.1038/s41467-021-23657-0, published June 2021. (labbe2021thestudyof pages 1-2)
ARPP19 belongs to the evolutionarily conserved endosulfine family and is structurally adapted for regulation rather than catalysis. Its intrinsic disorder enables phosphorylation-dependent remodeling and multivalent binding to PP2A. Human NMR assignments were reported in 2020, providing a foundation for analyzing dynamics and PP2A recognition: https://doi.org/10.1007/s12104-020-09951-w. (thapa2021structuralinsightofa pages 53-56, thapa2021structuralinsightof pages 53-56)
Biophysical measurements found binding between ARPP19 and the PP2A A/scaffold subunit PR65α with KD = 7.9 ± 1.5 μM. Similar binding by phosphomimetic variants suggests that scaffold association may be phosphorylation-independent, while potent inhibition depends on the MASTL-site phosphate and engagement of the B55 holoenzyme. This distinction is important: generic binding to a PP2A subunit is not equivalent to catalytic inhibition of PP2A-B55. (thapa2021structuralinsightof pages 27-31)
ARPP19 and ENSA are homologous but functionally specialized in mammals. The 2023 analysis reported 76% overall peptide-sequence identity, rising to 89% across the C-terminal 88 residues. Despite this similarity, ARPP19 is dominant in mitosis in mouse fibroblasts, whereas ENSA has a clearer DNA-replication role. (diril2023geneticdissectionof pages 2-3)
The most plausible disease connection is that increased ARPP19 can suppress the tumor-suppressive actions of PP2A-B55 and facilitate proliferation. Evidence is strongest at the association and cell-model level, not at the level of a clinically validated driver.
A human hepatocellular-carcinoma study analyzed 36 cases and found higher ARPP19 expression associated with larger tumors: Spearman r = 0.43, p < 0.01; the clinicopathologic association had p = 0.009. Median relative expression was 1.6 in tumors >5 cm, compared with 0.52 in tumors ≤5 cm. Lentiviral knockdown reduced ARPP19 protein by 75.6% in HepG2 and 73.5% in SMMC-7721 cells at 72 hours, decreased proliferation and colony formation, and increased the G2/M DNA-content fraction by more than twofold. DOI: https://doi.org/10.3390/ijms16010178, online December 2014. (song2014increasedarpp19expression pages 4-8)
These data support functional dependence in HCC cell lines, but the patient cohort was small and predates current multi-omics standards. Elevated expression should therefore be considered a candidate biomarker rather than proof that ARPP19 is an initiating oncogene.
The human-platelet study demonstrates a real-world physiological implementation of the pathway outside cell division. ARPP19 integrates cyclic-nucleotide signaling with PP2A and downstream MAPK/PI3K-Akt phosphorylation. Because low-dose PP2A inhibition suppressed thrombin-induced aggregation, this axis may influence antiplatelet biology. Nevertheless, no ARPP19-selective antiplatelet drug or clinical assay was identified. (kumm2020thecellcycle pages 1-3)
Current translational work focuses more often on upstream MASTL, PP2A-B55 assembly, or PP2A modulators than on ARPP19 itself. ARPP19 is difficult to drug conventionally because it is small and intrinsically disordered, lacks an enzymatic pocket, and contacts PP2A through extended interfaces. The 2024 structural work may enable peptide, interface, or state-selective inhibitor design, but this remains preclinical. No approved drug, registered ARPP19-directed clinical implementation, or established companion diagnostic was identified in the retrieved literature.
High confidence: ARPP19 is an endosulfine-family, intrinsically disordered, nonenzymatic regulator whose MASTL-dependent phosphorylation converts it into a PP2A-B55 inhibitor/slow substrate. Its principal conserved function is preservation of mitotic CDK-substrate phosphorylation. This conclusion is supported by biochemical reconstitution, phosphosite experiments, phosphatase depletion, mammalian knockouts, and recent structural analysis. (labbe2021thestudyof pages 1-2, padi2024cryoemstructuresof pages 8-9, hached2019ensaandarpp19 pages 1-2)
Moderate-to-high confidence: ARPP19 is the dominant MASTL effector for mitosis in mammalian fibroblasts, whereas ENSA is more important in S phase. The evidence is strong in mouse embryos and MEFs, though complete tissue-specific human genetic validation is lacking. (hached2019ensaandarpp19 pages 1-2, diril2023geneticdissectionof pages 1-2)
Moderate confidence: Human S104 links cyclic-nucleotide pathways to ARPP19 regulation. Direct human platelet data establish phosphorylation and PP2A-mediated dephosphorylation, but not a universal function in human somatic cell cycles. The prophase-arrest function of the corresponding Xenopus S109 site should remain labeled as model-organism evidence. (labbe2021thestudyof pages 1-2, kumm2020thecellcycle pages 1-3)
Preliminary: ARPP19 overexpression may contribute to malignancy and treatment resistance. Existing human tumor associations and cell-line knockdowns are biologically plausible but do not yet establish clinical utility or therapeutic selectivity. (song2014increasedarpp19expression pages 4-8)
Key unresolved issues include the endogenous spatiotemporal localization of human ARPP19 during mitosis; the full physiological significance of human S104 phosphorylation; the relative contributions of ARPP19 and ENSA across human tissues; whether ARPP19 has PP2A targets beyond B55-containing holoenzymes under physiological conditions; and whether the FAM122A-to-ARPP19 handoff observed structurally can be therapeutically manipulated without disrupting essential cell division in normal tissues.
Overall, the most defensible functional annotation for human ARPP19/P56211 is: an intracellular, intrinsically disordered, phosphorylation-dependent inhibitor and slow substrate of PP2A-B55 that couples MASTL/Greatwall activity to maintenance of the mitotic phosphoproteome.
References
(labbe2021thestudyof pages 1-2): Jean Claude Labbé, Suzanne Vigneron, Francisca Méchali, Perle Robert, Sylvain Roque, Cindy Genoud, Perrine Goguet-Rubio, Phillipe Barthe, Gilles Labesse, Martin Cohen-Gonsaud, Anna Castro, and Thierry Lorca. The study of the determinants controlling arpp19 phosphatase-inhibitory activity reveals an arpp19/pp2a-b55 feedback loop. Nature Communications, Jun 2021. URL: https://doi.org/10.1038/s41467-021-23657-0, doi:10.1038/s41467-021-23657-0. This article has 20 citations and is from a highest quality peer-reviewed journal.
(kumm2020thecellcycle pages 1-3): Elena J. Kumm, Oliver Pagel, Stepan Gambaryan, Ulrich Walter, René P. Zahedi, Albert Smolenski, and Kerstin Jurk. The cell cycle checkpoint system mast(l)-ensa/arpp19-pp2a is targeted by camp/pka and cgmp/pkg in anucleate human platelets. Cells, 9:472, Feb 2020. URL: https://doi.org/10.3390/cells9020472, doi:10.3390/cells9020472. This article has 33 citations.
(hached2019ensaandarpp19 pages 1-2): Khaled Hached, Perrine Goguet, Sophie Charrasse, Suzanne Vigneron, Maria P. Sacristan, Thierry Lorca, and Anna Castro. Ensa and arpp19 differentially control cell cycle progression and development. The Journal of Cell Biology, 218:541-558, Jan 2019. URL: https://doi.org/10.1083/jcb.201708105, doi:10.1083/jcb.201708105. This article has 51 citations.
(song2014increasedarpp19expression pages 4-8): Haiyan Song, Jielu Pan, Yang Liu, Hongzhu Wen, Lei Wang, Jiefeng Cui, Yinkun Liu, Bing Hu, Zemin Yao, and Guang Ji. Increased arpp-19 expression is associated with hepatocellular carcinoma. International Journal of Molecular Sciences, 16:178-192, Dec 2014. URL: https://doi.org/10.3390/ijms16010178, doi:10.3390/ijms16010178. This article has 29 citations.
(thapa2021structuralinsightofa pages 53-56): CJ Thapa. Structural insight of pp2a inhibitor proteins and their interaction with pp2a aand b56-subunits. Unknown journal, 2021.
(thapa2021structuralinsightof pages 27-31): CJ Thapa. Structural insight of pp2a inhibitor proteins and their interaction with pp2a aand b56-subunits. Unknown journal, 2021.
(roivas2020interactionsofpp2aa pages 11-17): P Roivas. Interactions of pp2a inhibitor proteins with pp2a regulatory subunits. Unknown journal, 2020.
(andrade2017arpp16isa pages 4-4): Erika C. Andrade, Veronica Musante, Atsuko Horiuchi, Hideo Matsuzaki, A. Harrison Brody, Terence Wu, Paul Greengard, Jane R. Taylor, and Angus C. Nairn. Arpp-16 is a striatal-enriched inhibitor of protein phosphatase 2a regulated by microtubule-associated serine/threonine kinase 3 (mast 3 kinase). The Journal of Neuroscience, 37:2709-2722, Mar 2017. URL: https://doi.org/10.1523/jneurosci.4559-15.2017, doi:10.1523/jneurosci.4559-15.2017. This article has 50 citations.
(lemonnier2021themphaseregulatory pages 14-14): Tom Lemonnier, Enrico Maria Daldello, Robert Poulhe, Tran Le, Marika Miot, Catherine Jessus, and Aude Dupré. The m-phase regulatory phosphatase pp2a-b55δ opposes protein kinase a on arpp19 to initiate meiotic division. Nature Communications, Oct 2021. URL: https://doi.org/10.1038/s41467-021-22124-0, doi:10.1038/s41467-021-22124-0. This article has 17 citations and is from a highest quality peer-reviewed journal.
(hached2019ensaandarpp19 pages 10-13): Khaled Hached, Perrine Goguet, Sophie Charrasse, Suzanne Vigneron, Maria P. Sacristan, Thierry Lorca, and Anna Castro. Ensa and arpp19 differentially control cell cycle progression and development. The Journal of Cell Biology, 218:541-558, Jan 2019. URL: https://doi.org/10.1083/jcb.201708105, doi:10.1083/jcb.201708105. This article has 51 citations.
(padi2024cryoemstructuresof pages 8-9): SKR Padi, MR Vos, RJ Godek, JR Fuller, and T Kruse. Cryo-em structures of pp2a: b55–fam122a and pp2a: b55–arpp19. Unknown journal, 2024.
(diril2023geneticdissectionof pages 2-3): Muhammed Kasim Diril and Mehmet Erguven. Genetic dissection of the mastl-arpp19/ensa-pp2a-b55δ pathway in mammalian cells. Turkish Journal of Biochemistry, 48:190-202, Mar 2023. URL: https://doi.org/10.1515/tjb-2022-0191, doi:10.1515/tjb-2022-0191. This article has 1 citations.
(diril2023geneticdissectionof pages 9-12): Muhammed Kasim Diril and Mehmet Erguven. Genetic dissection of the mastl-arpp19/ensa-pp2a-b55δ pathway in mammalian cells. Turkish Journal of Biochemistry, 48:190-202, Mar 2023. URL: https://doi.org/10.1515/tjb-2022-0191, doi:10.1515/tjb-2022-0191. This article has 1 citations.
(diril2023geneticdissectionof pages 1-2): Muhammed Kasim Diril and Mehmet Erguven. Genetic dissection of the mastl-arpp19/ensa-pp2a-b55δ pathway in mammalian cells. Turkish Journal of Biochemistry, 48:190-202, Mar 2023. URL: https://doi.org/10.1515/tjb-2022-0191, doi:10.1515/tjb-2022-0191. This article has 1 citations.
(thapa2021structuralinsightof pages 53-56): CJ Thapa. Structural insight of pp2a inhibitor proteins and their interaction with pp2a aand b56-subunits. Unknown journal, 2021.